Document Detail


Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback.
MedLine Citation:
PMID:  23188540     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Gynecology clinic-based studies have consistently demonstrated that induced hypogonadism is accompanied by a decline in cognitive test performance. However, a recent study in healthy asymptomatic controls observed that neither induced hypogonadism nor estradiol replacement influenced cognitive performance. Thus, the effects of induced hypogonadism on cognition might not be uniformly experienced across individual women. Moreover, discrepancies in the effects of hypogonadism on cognition also could suggest the existence of specific risk phenotypes that predict a woman's symptomatic experience during menopause. In this study, we examined the effects of induced hypogonadism and ovarian steroid replacement on cognitive performance in healthy premenopausal women. Ovarian suppression was induced with a GnRH agonist (Lupron) and then physiologic levels of estradiol and progesterone were reintroduced in 23 women. Cognitive tests were administered during each hormone condition. To evaluate possible practice effects arising during repeated testing, an identical battery of tests was administered at the same time intervals in 11 untreated women. With the exception of an improved performance on mental rotation during estradiol, we observed no significant effects of estradiol or progesterone on measures of attention, concentration, or memory compared with hypogonadism. In contrast to studies in which a decline in cognitive performance was observed in women receiving ovarian suppression therapy for an underlying gynecologic condition, we confirm a prior report demonstrating that short-term changes in gonadal steroids have a limited effect on cognition in young, healthy women. Differences in the clinical characteristics of the women receiving GnRH agonists could predict a risk for ovarian steroid-related changes in cognitive performance during induced, and possibly, natural menopause.
Authors:
Peter J Schmidt; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn Gibson; David R Rubinow
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2012-11-28
Journal Detail:
Title:  Archives of women's mental health     Volume:  16     ISSN:  1435-1102     ISO Abbreviation:  Arch Womens Ment Health     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-16     Completed Date:  2013-07-01     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  9815663     Medline TA:  Arch Womens Ment Health     Country:  Austria    
Other Details:
Languages:  eng     Pagination:  47-58     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Attention / drug effects
Case-Control Studies
Cognition / drug effects*
Estradiol / pharmacology*
Female
Follow-Up Studies
Gonadotropin-Releasing Hormone / administration & dosage
Hormone Replacement Therapy
Humans
Hypogonadism / blood,  chemically induced*,  physiopathology,  psychology*
Injections, Intramuscular
Leuprolide / pharmacology*
Memory / drug effects
Ovary / drug effects*
Premenopause
Progesterone / pharmacology*
Psychiatric Status Rating Scales / statistics & numerical data
Grant Support
ID/Acronym/Agency:
ZIA MH002537-23/MH/NIMH NIH HHS; ZIA MH002874-06/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
33515-09-2/Gonadotropin-Releasing Hormone; 4G7DS2Q64Y/Progesterone; 4TI98Z838E/Estradiol; EFY6W0M8TG/Leuprolide
Comments/Corrections
Comment In:
J Urol. 2013 Jun;189(6):2253-4   [PMID:  23663631 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Liver Transplantation for Primary Hyperoxaluria Type 1: A Single-center Experience during Two Decade...
Next Document:  Tuning the solubility of boron nitride nanosheets in organic solvents by using block copolymer as a ...